BALANCE SHEETS

	March 31, 2024 March 31, 202			
	U.S. Dollars Unaudited			
ASSETS				
CURRENT ASSETS:				
Cash and cash equivalents	4,638	-		
Short-term bank deposits				
Marketable Securities				
Trade accounts receivable	736,702	6,176,186		
Other receivables and prepaid expenses:				
Prepaid expenses	20,000	20,000		
Government authorities	-			
Advances to suppliers	1,556	4,744		
Derivative instruments				
Intercompany balances	9,352,622	1,238,559		
Other				
TOTAL Other receivables and prepaid expenses	9,374,177	1,263,303		
Inventories	1,305,438	1,957,693		
TOTAL CURRENT ASSETS	11,420,956	9,397,183		
Long Term Receivables and Other Assets				
Long Term Marketable Securities				
O .	-	-		
ROU Assets, net				
FIXED ASSETS:				
Cost				
Less - accumulated depreciation				
r	-	-		
INTANGIBLE ASSETS AND DEFERRED COSTS, NET				
DEFERRED INCOME TAXES				
TOTAL ASSETS	\$ 11,420,956	\$ 9,397,183		

BALANCE SHEETS

	M	arch 31, 2024	March 31, 2023		
		U.S	. Dollar	s	
		Una	audited		
LIABILITIES AND SHAREHOLDERS' EQUITY					
CURRENT LIABILITIES:					
Short-term bank credit	\$	-	\$	(268,929)	
Current maturities of long-term debt					
Accounts payable:					
Trade payables		-		-	
Other current liabilities:					
Returns reserve		(59,134)		(14,794)	
Payable to Government Authorities		(157,089)		(185,019)	
Due to customers		(656,413)			
Lease Liability					
Employees and payroll accruals					
Deferred revenue					
Accrued income taxes					
Legal and audit fees					
Settlements and loss contingencies					
Accrued expenses		(934,881)		(956,140)	
Derivative instruments					
Suppliers of property, plant and equipment					
Payable on Purchase of treasury stock					
Payable on Purchase of Marketable Securities					
Other					
OTAL Other current liabilities		(1,807,518)		(1,155,954)	
TOTAL CURRENT LIABILITIES		(1,807,518)		(1,424,883)	
LONG-TERM LIABILITIES:					
Long-term debt, net of current maturities					
Deferred income taxes					
Derivative instruments					
Other long-term liabilities					
		-		-	
SHAREHOLDERS' EQUITY		(9,613,438)		(7,972,300)	
	\$	(11,420,956)	\$	(9,397,182)	
Date of approval of the		Willia	ım Coote	e	
financial statements		VP, Chief	Financia	l Officer	

STATEMENTS OF INCOME

	or the Year Ended rch 31, 2024	For the Year Ended March 31, 2023		
		. Dollars audited		
	 Cit		_	
Sales	\$ 5,217,203	\$	4,536,646	
Cost of sales	 2,168,670		2,194,078	
Gross profit	3,048,533		2,342,567	
Research and development	-			
Selling and marketing expenses	1,988,055		2,985,090	
Settlements and loss contingencies	-			
General and administrative expenses	769,396		258,147	
Operating income	291,082		(900,669)	
Financing income, net	35,066		164,866	
Other expenses	1,385,122		1,923,160	
Income before taxes on income	1,641,138		857,624	
Taxes on income	 		323	
Discontinued operation	 			
Net income for the period before subsidiaries and dividend	1,641,138		857,301	
Dividend income, net				
Subsidiaries	 			
Net income for the period	\$ 1,641,138	\$	857,301	

Alchemee Skincare Corporation

Changes in Shareholders' Equity

	Share Capital	Additional paid in capital	Accumulated other comprehensive loss	Treasury stock	Dividend	Retained Earnings	Total Shareholders' Equity
				U.S. Dollars			
				Un-audited			
Balance at March 31, 2023		-			-	(7,972,300)	(7,972,300)
Foreign Currency translation adjustments							-
Unrealized losses on available for sale marketble securities							-
Treasury stock							-
Net income						(1,641,138)	(1,641,138)
Balance at March 31, 2024		-			-	(9,613,438)	(9,613,438)